immatics Appoints Peter Chambré as Chairman

                 immatics Appoints Peter Chambré as Chairman

  PR Newswire

  TUEBINGEN, Germany, November 12, 2012

TUEBINGEN, Germany, November 12, 2012 /PRNewswire/ --

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company
developing advanced therapeutic vaccines that are active against cancer, today
announced the appointment of Peter Chambré as Chairman of the Board with
immediate effect. Peter Chambré has had extensive senior management experience
in the biopharmaceutical sector and now holds several Chairman positions in
the life sciences industry. He will replace Thomas Widmann, who has been
Chairman of the Company since 2004.

Peter Chambré was CEO of Cambridge Antibody Technology (CAT), from 2002 until
its acquisition by AstraZeneca in 2006. Before joining CAT, Peter Chambré was
Chief Operating Officer of Celera Genomics Group and, previously, CEO of
Bespak plc, a drug delivery company.

Following these major executive roles in the sector, Peter Chambré has held
several Chairman and Non-executive Director positions. From 2008-2010, he was
Chairman of ApaTech, a specialist in orthobiologic bone graft technologies,
which was acquired by Baxter Inc. in March 2010, and from 2006-2012,
Non-executive Director of BTG plc. Peter Chambré currently holds Chairman and
Non-executive Board roles with a number of companies.

Paul Higham, CEO of immatics , said: "I am delighted to welcome Peter as our
new Chairman. We are approaching a crucial period at immatics , and Peter's
experience and track record in successfully developing biopharmaceutical
companies will be invaluable, as we seek to produce a step-change in the
treatment of cancer and maximize returns to our investors."

Peter Chambré said: " immatics ' vaccines, based on the Company's highly
rational approach to cancer vaccine discovery, have already demonstrated very
promising results in clinical trials. With IMA901, immatics ' lead
multi-peptide based vaccine now in phase 3 development for renal cancer, and a
number of other projects in clinical development, this is an extremely
exciting company. On behalf of immatics , I would like to express my thanks to
Thomas Widmann for his very significant contribution to the development of the
Company over the past 8 years. I very much look forward to working with the
Board and management, as immatics aims to improve outcomes for cancer patients
and create value for all its stakeholders."

For additional information on immatics please visit http://www.immatics.com or
contact:

About  immatics

immatics biotechnologies is a clinical-stage biopharmaceutical company
developing advanced therapeutic vaccines that are active against cancer.
immatics ' lead product, IMA901, is in a pivotal phase 3 study after
completing a successful randomized phase 2 trial in renal cell carcinoma.
immatics ' pipeline also includes IMA910, which has reported improved overall
survival data in patients with advanced colorectal cancer (phase 1/2 study
completed), and IMA950, which is in phase 1 in patients with glioma.

immatics ' unique technology platform XPRESIDENT ^[ ^TM ^] discovers novel
relevant cancer antigens known to be expressed on tumor cells,
tumor-associated peptides (TUMAPs), as the basis for its vaccines. In contrast
to widely used existing in silico and indirect methods to identify peptide
antigens immatics ' TUMAPs are confirmed to be naturally expressed in primary
cancer tissue. TUMAPs activate white blood cells (so called cytotoxic T cells)
against tumor cells.

immatics ' vaccines contain multiple TUMAPs to maximize the chances of
clinical success by increasing the number of targets on cancer cells that they
address. Phase 2 results with IMA901 and IMA910 have shown significantly
better survival in patients who respond to multiple TUMAPs in both of these
vaccines.

immatics ' multi-peptide vaccines are 'drug like', i.e. fully synthetic,
off-the-shelf, easily scalable and stable.

immatics is based in Tuebingen and Martinsried (Munich), Germany.

Paul Higham, CEO Dr. Nikola Wiegeler, Assistant to the Management immatics
biotechnologies GmbH Phone: +49-7071-5397-110 E-mail: media@immatics.com
Citigate Dewe RogersonDavid Dible / Chris Gardner / Sita Shah Phone:
+44(0)207-638-9571 E-mail: david.dible@citigatedr.co.uk